### Learner Notification

**MED Learning Group**

**Clinical Conversations Exchange: A PCP-Obesity Specialist Collaboration Discussing the Most Undertreated Chronic Disease: Evidence-based Obesity Management**

**Various Dates, 2023  
Online**

**Acknowledgement of Financial Commercial Support**

Lilly

**Acknowledgement of In-Kind Commercial Support**

No in-kind commercial support was received for this educational activity.

**Satisfactory Completion**

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

**Joint Accreditation Statement**

A picture containing drawing

Description automatically generatedIn support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Nurses (ANCC) Credit Designation**

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

###### Objectives - After Attending This Program You Should Be Able To

1. Analyze the metabolic and hormonal pathways involved in the pathophysiology of obesity.
2. Select diagnostic strategies and interventions for obesity using guidelines and clinical data.
3. Distinguish between anti - obesity medications based on their safety, efficacy and mechanisms of action.

**Disclosure of Conflict of Interest**

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

|  |  |  |
| --- | --- | --- |
| **First Name** | **Last Name** | **Commercial Interest: Relationship** |
| Russie | Allen | NA |
| Fatima | Cody Stanford, MD, MPH MPA, FAAP, FACP, FAHA, FAMWA, FTOS | Novo Nordisk, Boehringer Ingelheim, Pfizer, Currax, Eli Lilly, Rhythm, Gelesis, Coral Health, Calibrate, Veri, LifeForce, Sweetch, GoodRX: Consultant |
| Douglas | Cox | NA |
| Matthew | Frese | NA |
| Christina | Gallo | NA |
| Alexis | Klinger | NA |
| Cindy | Lampner | NA |
| Marissa | Mays-Verman | NA |
| Kim | Pfotenhauer DO, FACOFP | NA |
| Jay | Shubrook, DO | Abbott, Bayer, Novo Nordisk: Consultant; Abbott, AstraZeneca, Bayer, Eli Lilly, Nervo, Novo Nordisk: Advisory Board |
| Jo | Shultz | NA |
| Lauren | Welch | NA |

Questions? Email [Certificate@AmedcoEmail.com](mailto:Certificate@AmedcoEmail.com)